1. Home
  2. PVH vs CELC Comparison

PVH vs CELC Comparison

Compare PVH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PVH Corp.

PVH

PVH Corp.

HOLD

Current Price

$92.89

Market Cap

4.0B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$121.88

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVH
CELC
Founded
1881
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.1B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
PVH
CELC
Price
$92.89
$121.88
Analyst Decision
Buy
Strong Buy
Analyst Count
16
8
Target Price
$90.53
$107.88
AVG Volume (30 Days)
1.4M
674.2K
Earning Date
06-03-2026
05-13-2026
Dividend Yield
0.15%
N/A
EPS Growth
N/A
N/A
EPS
0.52
N/A
Revenue
$8,950,200,000.00
N/A
Revenue This Year
$1.89
N/A
Revenue Next Year
$1.86
$720.19
P/E Ratio
$189.90
N/A
Revenue Growth
3.44
N/A
52 Week Low
$59.60
$9.64
52 Week High
$100.00
$127.34

Technical Indicators

Market Signals
Indicator
PVH
CELC
Relative Strength Index (RSI) 68.05 55.46
Support Level $73.26 $99.38
Resistance Level N/A N/A
Average True Range (ATR) 4.05 5.65
MACD 0.97 0.44
Stochastic Oscillator 75.01 66.46

Price Performance

Historical Comparison
PVH
CELC

About PVH PVH Corp.

PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, roughly 1,400 standalone stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: